BMRN 87.60 Biomarin Pharmaceutical Inc $BMRN Hit a 52 week high of 88.23 Closing the day 11/10/14 at 87.60 +3.69 +4.40% With a day low of 85.78 and a total volume of 1,378,688.
BMRN Recent Posts: http://investorshangout.com/Biomarin-Pharmace...MRN-53520/
BMRN Biomarin Pharmaceutical Inc Recent Headline News
Look for Shares of BioMarin Pharmaceutical to Potentially Pullback after Yesterday's 4.40% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:35PM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $85.78 to a high of $88.23. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $84.42 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 87.60 (+3.69)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago BioMarin Pharmaceutical Is Up 11.9% (BMRN)
Comtex SmarTrend(R) - Mon Nov 10, 12:40PM CST
Two weeks ago on October 23rd, 2014 BioMarin Pharmaceutical (NASDAQ:BMRN) reported earnings and analysts, on average, expected a loss of $0.07 on sales of $170.1 million. The company actually reported a loss of $0.16 per share on sales of $176.8 million, missing EPS estimates by $0.09 and beating revenue estimates by $6.7 million. Shares of BioMarin Pharmaceutical have climbed from $75.01 to $83.91, representing a gain of 11.9% since the company reported earnings 18 days ago.
BMRN: 87.60 (+3.69)
Upgrade Alert for BioMarin Pharmaceutical (BMRN)
Comtex SmarTrend(R) - Mon Nov 10, 7:56AM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded from Neutral to Buy at Goldman Sachs today. The stock closed yesterday at $83.91 on volume of 727,000 shares, below average daily volume of 1.2 million. In the past 52 weeks, shares of BioMarin Pharmaceutical have traded between a low of $55.04 and a high of $86.80 and closed yesterday at $83.91, which is 52% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.8% while the 200-day MA has risen 0.4%.
BMRN: 87.60 (+3.69)
Shares of BMRN Up 13.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 05, 10:01AM CST
SmarTrend identified an Uptrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on October 21st, 2014 at $73.58. In approximately 2 weeks, BioMarin Pharmaceutical has returned 13.66% as of today's recent price of $83.63.
BMRN: 87.60 (+3.69)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 93.23 (+2.17), VRTX: 116.94 (+1.01), BMRN: 87.60 (+3.69), GILD: 107.02 (+0.57), ALXN: 195.80 (+1.99)
Why BioMarin Pharmaceutical Inc. Roared 14% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 9:01AM CST
BMRN data by YCharts What: Shares of BioMarin Pharmaceutical , a biopharmaceutical company focused on developing therapies to treat rare and ultra-rare diseases and disorders, roared higher by 14% in October, based on data from S&P...
BMRN: 87.60 (+3.69)
Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Tue Nov 04, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that Jean-Jacques Bienaime, Chief Executive Officer at BioMarin, will present at the Credit Suisse 2014 Healthcare Conference on Tuesday, November 11, 2014 at 1:30pm MT.
BMRN: 87.60 (+3.69)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 87.60 (+3.69), ISIS: 47.23 (+2.64), SGEN: 36.90 (+0.85), GILD: 107.02 (+0.57), SSYS: 104.89 (+1.82), HP: 86.40 (-0.30), REGN: 385.97 (+8.13), CELG: 108.01 (+1.56)
Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 186.99 (+0.84), GE: 26.47 (+0.06), BMRN: 87.60 (+3.69), IDXX: 147.18 (+2.02), GSK: 45.16 (+0.25), NVS: 92.63 (+0.87)
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:54AM CDT
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue?
BMRN: 87.60 (+3.69)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose a little over 8% on the day.
MDVN: 108.95 (-3.82), MACK: 8.70 (unch), BMRN: 87.60 (+3.69), ILMN: 188.27 (+1.92)
The 5 Most Expensive Drugs in the World
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 26, 11:21AM CDT
Source: StockMonkeys.com via Flickr . Whether you're prepared for it or not, prescription drug prices remain on the rise within the United States. Overall medical cost inflation may be at a multi-decade low in the U.S., but that doesn't seem to...
MNK: 93.23 (+2.17), VRTX: 116.94 (+1.01), BMRN: 87.60 (+3.69), SHPG: 200.98 (+2.40), ALXN: 195.80 (+1.99)
After Yesterday's Rally of 8.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Oct 24, 4:47PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $75.40 to a high of $81.83. Yesterday, the shares gained 8.0%, which took the trading range above the 3-day high of $75.86 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 87.60 (+3.69)
BioMarin Q3 Loss Narrower than Expected, View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:12PM CDT
BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected third-quarter 2014 loss of 16 cents per share.
MDVN: 108.95 (-3.82), BMRN: 87.60 (+3.69), ILMN: 188.27 (+1.92), SNY: 46.19 (+0.50)
BioMarin Pharmaceutical's (BMRN) CEO Jean-Jacques Bienaimé on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 23, 9:50PM CDT
BMRN: 87.60 (+3.69)
BioMarin Pharmaceutical Inc. Earnings: Striving to Be a Blockbuster Company
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 23, 7:38PM CDT
Every biotech dreams of having a blockbuster drug with annual sales higher than $1 billion. But ultra-orphan-drugmaker BioMarin Pharmaceuticals has a more realistic short-term goal: have $1 billion in sales for biotech's basket of five drugs. ...
BMRN: 87.60 (+3.69), SNY: 46.19 (+0.50)
Biomarin Q3 sales up 29%
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:15PM CDT
BMRN: 87.60 (+3.69)
BioMarin Pharmaceutical beats by $0.07, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 3:10PM CDT
BMRN: 87.60 (+3.69)
BioMarin Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 3:02PM CDT
- VIMIZIM Sales Top $25 million in Second Full Quarter of Sales
BMRN: 87.60 (+3.69)
BMRN Recent Posts: http://investorshangout.com/Biomarin-Pharmace...MRN-53520/
BMRN Biomarin Pharmaceutical Inc Recent Headline News
Look for Shares of BioMarin Pharmaceutical to Potentially Pullback after Yesterday's 4.40% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:35PM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $85.78 to a high of $88.23. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $84.42 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 87.60 (+3.69)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago BioMarin Pharmaceutical Is Up 11.9% (BMRN)
Comtex SmarTrend(R) - Mon Nov 10, 12:40PM CST
Two weeks ago on October 23rd, 2014 BioMarin Pharmaceutical (NASDAQ:BMRN) reported earnings and analysts, on average, expected a loss of $0.07 on sales of $170.1 million. The company actually reported a loss of $0.16 per share on sales of $176.8 million, missing EPS estimates by $0.09 and beating revenue estimates by $6.7 million. Shares of BioMarin Pharmaceutical have climbed from $75.01 to $83.91, representing a gain of 11.9% since the company reported earnings 18 days ago.
BMRN: 87.60 (+3.69)
Upgrade Alert for BioMarin Pharmaceutical (BMRN)
Comtex SmarTrend(R) - Mon Nov 10, 7:56AM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded from Neutral to Buy at Goldman Sachs today. The stock closed yesterday at $83.91 on volume of 727,000 shares, below average daily volume of 1.2 million. In the past 52 weeks, shares of BioMarin Pharmaceutical have traded between a low of $55.04 and a high of $86.80 and closed yesterday at $83.91, which is 52% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.8% while the 200-day MA has risen 0.4%.
BMRN: 87.60 (+3.69)
Shares of BMRN Up 13.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 05, 10:01AM CST
SmarTrend identified an Uptrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on October 21st, 2014 at $73.58. In approximately 2 weeks, BioMarin Pharmaceutical has returned 13.66% as of today's recent price of $83.63.
BMRN: 87.60 (+3.69)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 93.23 (+2.17), VRTX: 116.94 (+1.01), BMRN: 87.60 (+3.69), GILD: 107.02 (+0.57), ALXN: 195.80 (+1.99)
Why BioMarin Pharmaceutical Inc. Roared 14% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 9:01AM CST
BMRN data by YCharts What: Shares of BioMarin Pharmaceutical , a biopharmaceutical company focused on developing therapies to treat rare and ultra-rare diseases and disorders, roared higher by 14% in October, based on data from S&P...
BMRN: 87.60 (+3.69)
Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Tue Nov 04, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that Jean-Jacques Bienaime, Chief Executive Officer at BioMarin, will present at the Credit Suisse 2014 Healthcare Conference on Tuesday, November 11, 2014 at 1:30pm MT.
BMRN: 87.60 (+3.69)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 87.60 (+3.69), ISIS: 47.23 (+2.64), SGEN: 36.90 (+0.85), GILD: 107.02 (+0.57), SSYS: 104.89 (+1.82), HP: 86.40 (-0.30), REGN: 385.97 (+8.13), CELG: 108.01 (+1.56)
Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 186.99 (+0.84), GE: 26.47 (+0.06), BMRN: 87.60 (+3.69), IDXX: 147.18 (+2.02), GSK: 45.16 (+0.25), NVS: 92.63 (+0.87)
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:54AM CDT
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue?
BMRN: 87.60 (+3.69)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose a little over 8% on the day.
MDVN: 108.95 (-3.82), MACK: 8.70 (unch), BMRN: 87.60 (+3.69), ILMN: 188.27 (+1.92)
The 5 Most Expensive Drugs in the World
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 26, 11:21AM CDT
Source: StockMonkeys.com via Flickr . Whether you're prepared for it or not, prescription drug prices remain on the rise within the United States. Overall medical cost inflation may be at a multi-decade low in the U.S., but that doesn't seem to...
MNK: 93.23 (+2.17), VRTX: 116.94 (+1.01), BMRN: 87.60 (+3.69), SHPG: 200.98 (+2.40), ALXN: 195.80 (+1.99)
After Yesterday's Rally of 8.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Oct 24, 4:47PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $75.40 to a high of $81.83. Yesterday, the shares gained 8.0%, which took the trading range above the 3-day high of $75.86 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 87.60 (+3.69)
BioMarin Q3 Loss Narrower than Expected, View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:12PM CDT
BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected third-quarter 2014 loss of 16 cents per share.
MDVN: 108.95 (-3.82), BMRN: 87.60 (+3.69), ILMN: 188.27 (+1.92), SNY: 46.19 (+0.50)
BioMarin Pharmaceutical's (BMRN) CEO Jean-Jacques Bienaimé on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 23, 9:50PM CDT
BMRN: 87.60 (+3.69)
BioMarin Pharmaceutical Inc. Earnings: Striving to Be a Blockbuster Company
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 23, 7:38PM CDT
Every biotech dreams of having a blockbuster drug with annual sales higher than $1 billion. But ultra-orphan-drugmaker BioMarin Pharmaceuticals has a more realistic short-term goal: have $1 billion in sales for biotech's basket of five drugs. ...
BMRN: 87.60 (+3.69), SNY: 46.19 (+0.50)
Biomarin Q3 sales up 29%
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:15PM CDT
BMRN: 87.60 (+3.69)
BioMarin Pharmaceutical beats by $0.07, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 3:10PM CDT
BMRN: 87.60 (+3.69)
BioMarin Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 3:02PM CDT
- VIMIZIM Sales Top $25 million in Second Full Quarter of Sales
BMRN: 87.60 (+3.69)
